AU2013331049B2 - Broadly-neutralizing anti-HIV antibodies - Google Patents

Broadly-neutralizing anti-HIV antibodies Download PDF

Info

Publication number
AU2013331049B2
AU2013331049B2 AU2013331049A AU2013331049A AU2013331049B2 AU 2013331049 B2 AU2013331049 B2 AU 2013331049B2 AU 2013331049 A AU2013331049 A AU 2013331049A AU 2013331049 A AU2013331049 A AU 2013331049A AU 2013331049 B2 AU2013331049 B2 AU 2013331049B2
Authority
AU
Australia
Prior art keywords
seq
nos
antibody
hiv
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013331049A
Other languages
English (en)
Other versions
AU2013331049A1 (en
Inventor
Pamela J. Bjorkman
Hugo MOUQUET
Michel Nussenzweig
Louise Scharf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
California Institute of Technology
Original Assignee
Rockefeller University
California Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, California Institute of Technology filed Critical Rockefeller University
Publication of AU2013331049A1 publication Critical patent/AU2013331049A1/en
Application granted granted Critical
Publication of AU2013331049B2 publication Critical patent/AU2013331049B2/en
Priority to AU2019201039A priority Critical patent/AU2019201039B2/en
Priority to AU2020244391A priority patent/AU2020244391B2/en
Priority to AU2023201926A priority patent/AU2023201926B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2013331049A 2012-10-18 2013-10-18 Broadly-neutralizing anti-HIV antibodies Active AU2013331049B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2019201039A AU2019201039B2 (en) 2012-10-18 2019-02-14 Broadly-neutralizing anti-hiv antibodies
AU2020244391A AU2020244391B2 (en) 2012-10-18 2020-09-28 Broadly-neutralizing anti-hiv antibodies
AU2023201926A AU2023201926B2 (en) 2012-10-18 2023-03-29 Broadly-neutralizing anti-hiv antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715642P 2012-10-18 2012-10-18
US61/715,642 2012-10-18
PCT/US2013/065696 WO2014063059A1 (en) 2012-10-18 2013-10-18 Broadly-neutralizing anti-hiv antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201039A Division AU2019201039B2 (en) 2012-10-18 2019-02-14 Broadly-neutralizing anti-hiv antibodies

Publications (2)

Publication Number Publication Date
AU2013331049A1 AU2013331049A1 (en) 2015-04-16
AU2013331049B2 true AU2013331049B2 (en) 2018-11-15

Family

ID=50488789

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013331049A Active AU2013331049B2 (en) 2012-10-18 2013-10-18 Broadly-neutralizing anti-HIV antibodies
AU2019201039A Active AU2019201039B2 (en) 2012-10-18 2019-02-14 Broadly-neutralizing anti-hiv antibodies
AU2020244391A Active AU2020244391B2 (en) 2012-10-18 2020-09-28 Broadly-neutralizing anti-hiv antibodies
AU2023201926A Expired - Fee Related AU2023201926B2 (en) 2012-10-18 2023-03-29 Broadly-neutralizing anti-hiv antibodies

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2019201039A Active AU2019201039B2 (en) 2012-10-18 2019-02-14 Broadly-neutralizing anti-hiv antibodies
AU2020244391A Active AU2020244391B2 (en) 2012-10-18 2020-09-28 Broadly-neutralizing anti-hiv antibodies
AU2023201926A Expired - Fee Related AU2023201926B2 (en) 2012-10-18 2023-03-29 Broadly-neutralizing anti-hiv antibodies

Country Status (20)

Country Link
US (6) US10047146B2 (enExample)
EP (2) EP2908912B1 (enExample)
JP (6) JP6461804B2 (enExample)
CN (3) CN118955699A (enExample)
AU (4) AU2013331049B2 (enExample)
BR (1) BR112015008635B1 (enExample)
CA (2) CA3236192A1 (enExample)
CY (1) CY1124405T1 (enExample)
DK (1) DK2908912T3 (enExample)
EA (2) EA035012B1 (enExample)
ES (1) ES2822135T3 (enExample)
HR (1) HRP20201505T1 (enExample)
HU (1) HUE051577T2 (enExample)
IL (5) IL285049B (enExample)
LT (1) LT2908912T (enExample)
MX (2) MX376969B (enExample)
PL (1) PL2908912T3 (enExample)
PT (1) PT2908912T (enExample)
SI (1) SI2908912T1 (enExample)
WO (1) WO2014063059A1 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201639852A (zh) 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9783594B2 (en) 2011-05-17 2017-10-10 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CN118955699A (zh) * 2012-10-18 2024-11-15 洛克菲勒大学 广泛中和性抗hiv抗体
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
WO2014134547A1 (en) * 2013-02-28 2014-09-04 Therabiol, Inc. Hiv antigens and antibodies
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
EP4140485A1 (en) * 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
UY36298A (es) 2014-09-16 2016-04-29 Gilead Science Inc Formas sólidas de un modulador del receptor tipo toll
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
US10344077B2 (en) 2015-03-19 2019-07-09 Duke University HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)
CA2999917A1 (en) 2015-09-24 2017-03-30 Abvitro Llc Hiv antibody compositions and methods of use
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
TW201811376A (zh) 2016-07-01 2018-04-01 英商葛蘭素史密斯克藍智慧財產權有限公司 抗體-藥物結合物及使用其之治療方法
EP3525821A4 (en) 2016-10-17 2020-09-09 University of Maryland MULTI-SPECIFIC ANTIBODIES TARGETING THE HUMAN IMMUNODEFICIENCY VIRUS AND THEIR METHODS OF USE
CA3041310C (en) 2016-10-21 2023-09-05 Altor Bioscience Corporation Multimeric il-15-based molecules
JP7041898B2 (ja) * 2016-12-27 2022-03-25 ザ ロックフェラー ユニバーシティー 広域中和抗ｈｉｖ－１抗体およびその使用方法
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
WO2019165122A1 (en) * 2018-02-21 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
CA3100282A1 (en) 2018-06-19 2019-12-26 Nantcell, Inc. Hiv treatment compositions and methods
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
WO2020023827A1 (en) * 2018-07-27 2020-01-30 International Aids Vaccine Initiative Engineered antibodies to hiv env
US12441782B2 (en) 2018-09-14 2025-10-14 The Rockefeller University Anti-HIV antibody 10-1074 variants
KR20210133225A (ko) * 2019-01-28 2021-11-05 사이포스 바이오사이언시스 인코포레이티드 부착된 이종 분자를 car-세포의 비천연 nkg2d 수용체에 선택적으로 전달하는 변형된 비천연 nkg2d 리간드
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
SI3938047T1 (sl) 2019-03-22 2022-10-28 Gilead Sciences, Inc. Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
EP3947445A1 (en) * 2019-04-04 2022-02-09 Vanderbilt University Hiv/hcv cross-reactive antibodies and uses thereof
TW202231277A (zh) 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
JP7454645B2 (ja) 2019-07-16 2024-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン並びにその作製方法及び使用方法
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN112759651B (zh) * 2019-11-01 2022-09-20 北京华夏清医治疗科技有限公司 一种包含嵌合抗原受体修饰的t细胞及其应用
EP3831848A1 (en) * 2019-12-02 2021-06-09 Universität zu Köln Broadly neutralizing antibodies against hiv
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
TWI845826B (zh) 2020-03-20 2024-06-21 美商基利科學股份有限公司 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
MX2023001507A (es) 2020-08-07 2023-03-06 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico.
PH12023500005A1 (en) 2020-08-25 2023-08-14 Gilead Sciences Inc Multi-specific antigen binding molecules targeting hiv and methods of use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20220144923A1 (en) 2020-11-11 2022-05-12 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CN118355020A (zh) 2021-12-03 2024-07-16 吉利德科学公司 Hiv病毒感染的治疗性化合物
FI4445900T3 (fi) 2021-12-03 2025-08-05 Gilead Sciences Inc Terapeuttisia yhdisteitä hiv-virusinfektiota varten
AU2022409827A1 (en) 2021-12-17 2024-06-20 Viiv Healthcare Company Combination therapies for hiv infections and uses thereof
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
EP4547659A1 (en) 2022-07-01 2025-05-07 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
CA3265134A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. DOSING AND PLANNING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
AU2024259111A1 (en) 2023-04-19 2025-10-16 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025050404A1 (zh) * 2023-09-08 2025-03-13 成都维瑾柏鳌生物医药科技有限公司 一种药物组合物及其应用
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250120989A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030904A2 (en) * 2010-08-31 2012-03-08 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US81A (en) 1836-11-15 Erawijjg
US6593A (en) 1849-07-17 Cutting
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5798251A (en) * 1990-05-29 1998-08-25 Cedars-Sinai Medical Center Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
CA2436091A1 (en) 2001-01-26 2002-08-01 Abgenix, Inc. Neutralizing human monoclonal antibodies against hiv-1, their production and uses
EP1504034B1 (en) * 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US7501494B2 (en) * 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
WO2004089182A2 (en) * 2003-04-14 2004-10-21 Children's National Medical Center Anti-retroviral analysis by mass spectrometry
JP4568896B2 (ja) * 2003-12-16 2010-10-27 財団法人くまもとテクノ産業財団 抗ｈｉｖ抗体
DE602005027809D1 (de) * 2004-01-07 2011-06-16 Hitachi Chemical Co Ltd Primer und sonden zum nachweis von hiv
JP4895727B2 (ja) * 2006-08-28 2012-03-14 シスメックス株式会社 抗ｈｉｖ抗体検出試薬、試薬キット、試薬の製造方法、及び抗ｈｉｖ抗体の検出方法
WO2008140579A2 (en) 2006-11-17 2008-11-20 New York University Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope
EP2178560A2 (en) 2007-07-23 2010-04-28 Maxygen, Inc. Chimeric hiv antigens
JP2012512663A (ja) * 2008-12-19 2012-06-07 アボット・ラボラトリーズ Ｈｉｖ指向性を診断するための分子アッセイ
WO2011092593A2 (en) 2010-01-20 2011-08-04 Institute For Research In Biomedicine Hiv-1 neutralizing antibodies and uses thereof
RU2535034C2 (ru) 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
US9360483B2 (en) 2010-12-01 2016-06-07 Albert Einstein College Of Medicine, Inc. Constructs and methods to identify antibodies that target glycans
CN118955699A (zh) 2012-10-18 2024-11-15 洛克菲勒大学 广泛中和性抗hiv抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030904A2 (en) * 2010-08-31 2012-03-08 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies

Also Published As

Publication number Publication date
CA3236192A1 (en) 2014-04-24
US20220002390A1 (en) 2022-01-06
CA2888659A1 (en) 2014-04-24
CN112920269A (zh) 2021-06-08
JP7376898B2 (ja) 2023-11-09
CN104918658B (zh) 2021-02-19
SI2908912T1 (sl) 2021-03-31
IL293362B1 (en) 2023-04-01
BR112015008635B1 (pt) 2023-10-31
JP2025118727A (ja) 2025-08-13
US12338277B2 (en) 2025-06-24
CY1124405T1 (el) 2022-03-24
EA035012B1 (ru) 2020-04-17
IL301018A (en) 2023-05-01
HUE051577T2 (hu) 2021-03-01
US20190345233A1 (en) 2019-11-14
EP3783018A1 (en) 2021-02-24
WO2014063059A1 (en) 2014-04-24
JP2022115946A (ja) 2022-08-09
AU2023201926A1 (en) 2023-05-04
AU2020244391A1 (en) 2020-10-29
JP2015534982A (ja) 2015-12-07
EP2908912A1 (en) 2015-08-26
US10047146B2 (en) 2018-08-14
LT2908912T (lt) 2020-09-25
US20230279082A1 (en) 2023-09-07
CN118955699A (zh) 2024-11-15
PT2908912T (pt) 2020-09-04
MX2015004924A (es) 2015-10-29
US11649276B2 (en) 2023-05-16
EA201590741A1 (ru) 2015-09-30
JP2021003104A (ja) 2021-01-14
CN104918658A (zh) 2015-09-16
DK2908912T3 (da) 2020-10-26
AU2019201039B2 (en) 2020-08-27
US11142564B2 (en) 2021-10-12
JP7681278B2 (ja) 2025-05-22
EA201992107A1 (ru) 2020-04-30
IL285049A (en) 2021-08-31
US20250320280A1 (en) 2025-10-16
HRP20201505T1 (hr) 2020-12-11
BR112015008635A2 (pt) 2018-09-04
CA2888659C (en) 2024-06-04
MX376969B (es) 2025-03-07
US20150274813A1 (en) 2015-10-01
EP2908912A4 (en) 2016-05-25
IL301018B1 (en) 2025-11-01
ES2822135T3 (es) 2021-04-29
JP6461804B2 (ja) 2019-01-30
JP2019071888A (ja) 2019-05-16
AU2019201039A1 (en) 2019-03-07
JP6732872B2 (ja) 2020-07-29
PL2908912T3 (pl) 2021-05-17
IL238320B (en) 2021-08-31
IL238320A0 (en) 2015-06-30
US10392433B2 (en) 2019-08-27
EP2908912B1 (en) 2020-08-05
AU2020244391B2 (en) 2023-02-16
AU2023201926B2 (en) 2025-08-14
AU2013331049A1 (en) 2015-04-16
CN112920269B (zh) 2024-05-24
IL293362B2 (en) 2023-08-01
JP2024010023A (ja) 2024-01-23
US20180282400A1 (en) 2018-10-04
MX2020011669A (es) 2021-02-15
IL285049B (en) 2022-07-01
IL293362A (en) 2022-07-01
JP7076722B2 (ja) 2022-05-30
IL323371A (en) 2025-11-01
HK1212935A1 (en) 2016-06-24

Similar Documents

Publication Publication Date Title
AU2013331049B2 (en) Broadly-neutralizing anti-HIV antibodies
AU2019200972A1 (en) Human immunodeficiency virus neutralising antibodies and methods of use thereof
HK40044714A (en) Broadly-neutralizing anti-hiv antibodies
HK1212935B (en) Broadly-neutralizing anti-hiv antibodies
EA046696B1 (ru) Биспецифическое анти-вич-антитело и его применение

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MOUQUET, HUGO; NUSSENZWEIG, MICHEL; BJORKMAN, PAMELA J. AND SCHARF, LOUISE

FGA Letters patent sealed or granted (standard patent)